Michael Maraist an Insider in Home Bancorp, Inc. (HBCP), Picked up 2,000 Shares of the Company; Last Week Enanta Pharmaceuticals, Inc. (ENTA) Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Enanta Pharmaceuticals Inc has $58.0 highest and $16 lowest target. $35.20’s average target is -52.57% below currents $74.22 stock price. Enanta Pharmaceuticals Inc had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was maintained by Robert W. Baird with “Hold” on Friday, October 20. Zacks downgraded Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Friday, August 7 to “Buy” rating. As per Friday, October 23, the company rating was downgraded by Barclays Capital. As per Monday, November 20, the company rating was maintained by RBC Capital Markets. The rating was downgraded by TheStreet on Saturday, August 8 to “Buy”. JMP Securities upgraded the stock to “Market Outperform” rating in Tuesday, July 11 report. The stock has “Hold” rating by Robert W. Baird on Monday, November 20. The firm has “Mkt Outperform” rating given on Friday, October 23 by JMP Securities. The rating was maintained by JP Morgan on Tuesday, August 9 with “Overweight”. The stock of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) earned “Market Perform” rating by JMP Securities on Thursday, April 28. See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) latest ratings:

02/01/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Sector Perform Old Target: $54 Downgrade
20/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $46.0 Maintain
20/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $58.0 Maintain
20/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $36.0 Maintain
20/10/2017 Broker: RBC Capital Markets Rating: Buy New Target: $54.0 Maintain
15/09/2017 Broker: Robert W. Baird Rating: Hold New Target: $36.0 Maintain
15/09/2017 Broker: RBC Capital Markets Rating: Outperform New Target: $54 Initiates Coverage On
08/08/2017 Broker: Robert W. Baird Rating: Neutral Old Target: $27 New Target: $36 Maintain

As shown in an electronic form that was submitted to the Washington-based SEC on January 25, 2018, Michael Maraist an insider in Home Bancorp Inc and currently director, invested in shares worth $30,870 U.S. Dollars in the stock exchange listed company. He acquired 2,000 new shares, at average $15.4 per share. At the moment, he owns 150,976 shares or around 2.03% of Home Bancorp Inc’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding).

Home Bancorp, Inc. operates as the holding firm for Home Bank, National Association that provides various banking services and products in Louisiana. The company has market cap of $315.18 million. It offers deposits products, including interest-bearing and noninterest-bearing checking, money market, savings, and certificates of deposit accounts. It has a 17.07 P/E ratio. The firm also provides various loan products, such as one-to-four-family first mortgage loans, home equity loans and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.

The stock increased 0.17% or $0.07 during the last trading session, reaching $42.33. About 9,852 shares traded. Home Bancorp, Inc. (NASDAQ:HBCP) has risen 24.80% since January 26, 2017 and is uptrending. It has outperformed by 8.10% the S&P500.

Among 2 analysts covering Home Bancorp (NASDAQ:HBCP), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Home Bancorp has $46 highest and $29 lowest target. $37.50’s average target is -11.41% below currents $42.33 stock price. Home Bancorp had 4 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, September 30 by Raymond James. On Wednesday, October 18 the stock rating was maintained by Sandler O’Neill with “Hold”. The stock has “Buy” rating by Zacks on Thursday, August 13. The firm has “Market Perform” rating given on Wednesday, July 26 by Raymond James.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.42 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 81.56 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

Investors sentiment increased to 1.6 in 2017 Q3. Its up 0.75, from 0.85 in 2017Q2. It improved, as 9 investors sold Enanta Pharmaceuticals, Inc. shares while 31 reduced holdings. 16 funds opened positions while 48 raised stakes. 12.10 million shares or 2.87% more from 11.77 million shares in 2017Q2 were reported. 56,419 are held by Schwab Charles Management Inc. Price T Rowe Inc Md invested in 0% or 102,444 shares. D E Shaw & Comm holds 19,632 shares. Sg Americas Secs Ltd Liability Corporation reported 5,662 shares. Jpmorgan Chase Co accumulated 115,977 shares. Nationwide Fund Advsrs has invested 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Tiaa Cref Investment Mngmt Ltd Liability Corporation reported 41,084 shares or 0% of all its holdings. 157,993 were accumulated by Aqr Cap Management Lc. Alps Advsrs reported 0.01% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). 12,112 are held by Gotham Asset Mngmt Ltd Limited Liability Company. Barclays Plc reported 0% stake. American Intll Grp Inc invested 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). State Board Of Administration Of Florida Retirement reported 0% stake. Goldman Sachs Group holds 84,035 shares or 0% of its portfolio. State Of Alaska Department Of Revenue owns 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 2,750 shares.